Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24


19391 items
3:52 PM, Jul 20, 2018  |  BioCentury | Finance

JOBS Jolt 3.0?

The latest iteration of the JOBS Act could make it easier for biotechs to go public -- and raise more money more quickly -- but that doesn’t necessarily mean the quality of the IPO queue...
1:26 PM, Jul 20, 2018  |  BioCentury | Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
10:45 AM, Jul 18, 2018  |  BioCentury | Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday, joined...
4:00 AM, Jul 16, 2018  |  BioCentury | Finance

AI on the Verge

For its $32 million series A round, artificial intelligence-guided neurology company Verge Genomics Inc. sought an investor syndicate that reflected its multidisciplinary mind-set. DFJ led the round. New investors included the corporate venture fund of WuXi...
4:21 PM, Jul 13, 2018  |  BioCentury | Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
2:52 PM, Jul 13, 2018  |  BioCentury | Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
11:49 AM, Jul 13, 2018  |  BioCentury | Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
10:54 AM, Jul 13, 2018  |  BioCentury | Finance

Forbion builds immunity

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in...
11:35 AM, Jul 12, 2018  |  BioCentury | Regulation

Making patients partners

FDA has rolled out the first of a series of planned guidance documents aimed at creating a road map for making patient experience data integral to every phase of medical product development. The guidance documents,...
4:02 PM, Jul 09, 2018  |  BioCentury | Finance

A Wellcome leap for blue sky funding

The Wellcome Trust is putting £250 million ($333.5 million) on the line to back blue sky life sciences ideas that would otherwise be too risky to attract early stage funding. The non-profit Leap Fund will allocate...